TGA Of Australia Eyes U.S. Counterpart's Avandia Decisions
This article was originally published in PharmAsia News
Australia's Therapeutic Goods Administration, which already had ordered increased warnings on the labels for GlaxoSmithKline's Avandia (rosiglitazone) diabetes drug, is watching U.S. actions before taking further action
You may also be interested in...
Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.
The FDA must report to the House Appropriations Committee on any work toward defining “natural” cosmetics and on the health effects of talc, asbestos and lead in cosmetic products. The committee’s 2021 FDA spending bill report also cites concerns about skin-lightening products containing “dangerous levels of mercury and hydroquinone.”
Verrica got a complete response rather than approval for its drug/device combo for molluscum, but says the FDA only needs additional information on product changes for safe usage by clinicians.